FDA drug review

An earnout puts $700 million of Telix's price for ITM on meeting both regulatory and sales goals

Telix is buying privately held ITM in a merger STAT puts at a minimum of $1.65 billion, with another $700 million payable only if ITM's lead drug clears regulators and meets sales goals. STAT says the deal follows a surprise FDA rejection.